View Older Stories View More Recent Stories

May 19, 2026 02:16PM ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
May 19, 2026 07:31AM ImmunityBio presents bladder cancer treatment comparison data at AUA
May 18, 2026 03:02PM $IBRX DEADLINE: Immunitybio Inc. Investors Who Lost Money Should Contact Block & Leviton Before May 26th Deadline
May 18, 2026 01:01PM ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
May 18, 2026 07:31AM ImmunityBio receives five US patents for cancer drug combination
May 7, 2026 07:39AM ImmunityBio, Inc. (IBRX) Misses Q1 EPS by 55c
Apr 21, 2026 07:30AM ImmunityBio launches ANKTIVA cancer treatment in Saudi Arabia
Apr 9, 2026 07:31AM ImmunityBio reports Q1 revenue of $44 million, up 168% year-over-year
Apr 6, 2026 07:30AM ImmunityBio responds to FDA concerns over promotional materials
Mar 31, 2026 07:31AM ImmunityBio secures $100 million in financing with debt conversion
Mar 30, 2026 03:21PM ImmunityBio ALERT: $IBRX Investors Who Lost Money Should Contact Block & Leviton By May 26th To Potentially Recover Losses
Mar 26, 2026 07:30AM ImmunityBio bladder cancer trial meets statistical power requirements
Mar 24, 2026 12:52PM BTIG on Immunitybio Inc (IBRX): FDA warning letter issue 'likely resolvable,' selloff a buying oppty
Mar 24, 2026 10:44AM ImmunityBio shares plunge after FDA warning over misleading ads
Mar 24, 2026 09:27AM FDA issues warning letter to ImmunityBio over misleading ANKTIVA ads
Mar 20, 2026 01:08PM ImmunityBio receives approval for ANKTIVA in Macau for bladder cancer
Mar 17, 2026 07:31AM NCCN updates bladder cancer guidelines to include ImmunityBio's ANKTIVA
Mar 13, 2026 07:30AM ImmunityBio completes NK cell manufacturing programs with 74 subjects
Mar 11, 2026 04:11PM BTIG Assumes Immunitybio Inc (IBRX) at Buy
Mar 9, 2026 07:31AM ImmunityBio resubmits cancer treatment application to FDA
Mar 4, 2026 07:54AM Immunitybio Inc (IBRX) PT Raised to $12 at Piper Sandler
Feb 26, 2026 07:31AM ImmunityBio completes enrollment in bladder cancer trial ahead of schedule
Feb 25, 2026 03:09PM ImmunityBio (IBRX) January 5.5 puts active as share price down 14.5%
Feb 23, 2026 01:03PM Immunitybio Inc (IBRX) PT Raised to $15 at H.C. Wainwright
Feb 23, 2026 10:39AM Increasing unusual put option volume: FND BRBR XRX FSLY XLP LNC HBAN FEZ OKTA VICI VTRS IGV IBRX
Feb 23, 2026 08:17AM ImmunityBio, Inc. (IBRX) Tops Q4 EPS by 5c
Feb 23, 2026 07:01AM ImmunityBio reports 700% revenue growth, expands approvals globally
Feb 20, 2026 08:30AM ImmunityBio partners to launch ANKTIVA cancer drug in Saudi Arabia
Feb 19, 2026 09:02AM ImmunityBio partners with Accord Healthcare for European ANKTIVA launch
Feb 18, 2026 09:01AM ImmunityBio wins European approval for bladder cancer treatment
Feb 17, 2026 06:09AM ImmunityBio discusses drug approvals with Saudi regulators
Jan 26, 2026 06:49AM Immunitybio Inc (IBRX) PT Raised to $10 at H.C. Wainwright
Jan 23, 2026 07:00AM ImmunityBio reports survival data from glioblastoma trial
Jan 22, 2026 01:17PM Immunitybio Inc (IBRX) PT Raised to $9 at BTIG
Jan 21, 2026 10:09AM Increasing unusual call option volume: SAVA GORO IBRX VET XP IGV MRAM RMBS ONON BLDP
Jan 20, 2026 07:44AM Immunitybio Inc (IBRX) PT Raised to $7 at Piper Sandler
Jan 16, 2026 10:44AM Increasing unusual option volume: IRE IBRX QNCX FE IREX RVMD RPD
Jan 16, 2026 07:00AM ImmunityBio reports 15-month response in lymphoma cell therapy trial
Jan 16, 2026 07:00AM ImmunityBio reports progress in bladder cancer trial enrollment
Jan 15, 2026 08:41AM ImmunityBio releases preliminary 2025 financial results
Jan 15, 2026 08:32AM ImmunityBio reports $113 million revenue, 700% annual increase
Jan 14, 2026 08:30AM ImmunityBio gets Saudi approval for bladder cancer treatment ANKTIVA
Jan 13, 2026 08:30AM ImmunityBio reports positive lung cancer trial results for ANKTIVA
Dec 29, 2025 06:04AM ImmunityBio amends stock sale agreement to authorize $460M offering
Dec 21, 2025 04:00AM Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
Dec 16, 2025 09:01AM ImmunityBio's ANKTIVA shows 96% survival in bladder cancer study
Dec 12, 2025 11:37AM Immunitybio Inc (IBRX) PT Raised to $9 at Jefferies
Dec 12, 2025 06:10AM ImmunityBio gets european drug agency nod for bladder cancer treatment
Nov 5, 2025 01:58AM ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c
Sep 10, 2025 07:30AM H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)
View More Recent Stories View Older Stories